BlackRock, Inc. 13D and 13G filings for Cytokinetics, Incorporated:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-12 11:44 am Unchanged | 2024-09-30 | 13G | Cytokinetics, Incorporated CYTK | BlackRock Inc. BLK | 15,252,905 13.000% | 0 (Unchanged) | Filing |
| 2024-10-23 5:04 pm Sale | 2024-09-30 | 13G | Cytokinetics, Incorporated CYTK | BlackRock Inc. BLK | 15,252,905 13.000% | -1,047,636 (-6.43%) | Filing |
| 2024-01-22 2:03 pm Purchase | 2023-12-31 | 13G | Cytokinetics, Incorporated CYTK | BlackRock Inc. BLK | 16,300,541 16.400% | 532,667 (+3.38%) | Filing |
| 2023-02-10 2:11 pm Unchanged | 2022-12-31 | 13G | Cytokinetics, Incorporated CYTK | BlackRock Inc. BLK | 15,767,874 16.700% | 0 (Unchanged) | Filing |
| 2023-01-26 08:52 am Purchase | 2022-12-31 | 13G | Cytokinetics, Incorporated CYTK | BlackRock Inc. BLK | 15,767,874 16.000% | 800,557 (+5.35%) | Filing |
| 2023-01-20 3:00 pm Purchase | 2022-12-31 | 13G | Cytokinetics, Incorporated CYTK | BlackRock Inc. BLK | 14,967,317 16.000% | 2,016,353 (+15.57%) | Filing |
| 2022-01-27 1:59 pm Unchanged | 2021-12-31 | 13G | Cytokinetics, Incorporated CYTK | BlackRock Inc. BLK | 12,950,964 15.400% | 0 (Unchanged) | Filing |
| 2022-01-25 6:45 pm Purchase | 2021-12-31 | 13G | Cytokinetics, Incorporated CYTK | BlackRock Inc. BLK | 12,950,964 15.400% | 1,339,885 (+11.54%) | Filing |
| 2021-01-25 4:50 pm Purchase | 2020-12-31 | 13G | Cytokinetics, Incorporated CYTK | BlackRock Inc. BLK | 11,611,079 16.400% | 2,050,477 (+21.45%) | Filing |